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and Mary E. R. O’Brien, MD‡
Introduction: Lung cancer symptoms can be burdensome for pa-
tients with small cell lung cancer (SCLC). Patient Symptom Assess-
ment in Lung Cancer (PSALC), a self-report scale for assessing
SCLC symptom burden, was developed and validated previously
using intravenous topotecan clinical trial data. This study cross-
validates the PSALC using oral topotecan (OT) trial data.
Methods: Data were analyzed from a randomized, open-label,
multicenter trial including 71 patients with relapsed SCLC receiving
OT with best supportive care and 70 patients receiving best sup-
portive care alone. PSALC and EQ-5D were administered at base-
line and at 3-week intervals. Internal consistency, reliability, con-
struct validity, and responsiveness were evaluated.
Results: Only one factor was indicated in factor analysis, hence
PSALC total score (PSALC-TS) was used for psychometric analy-
sis. Internal consistency was supported by Cronbach’s alpha of 0.78.
Construct validity was supported by significant associations of
higher PSALC-TS (higher symptom burden) with worse Eastern
Cooperative Oncology Group performance status and by correla-
tions of PSALC-TS with EQ-5D utility index and visual analog
scale score (all p  0.001). Reliability was supported by intraclass
correlation coefficient of 0.68 (using PSALC-TS before clinical
status change) and concordance correlation coefficient of 0.69 (using
PSALC-TS at baseline and before first visit). PSALC-TS was
responsive to clinical status change from baseline to tumor response
(responsiveness statistic  0.99) and to tumor progression (re-
sponsiveness statistic  0.94).
Conclusions: Consistent with prior psychometric results, this cross-
validation study using OT trial data showed acceptable validity,
reliability, and responsiveness of the PSALC scale, further support-
ing its use to measure symptom burden in previously treated SCLC.
Key Words: Small cell lung cancer, Patient Symptom Assessment
in Lung Cancer instrument, Clinical trials, Psychometric validation,
Topotecan.
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Small cell lung cancer (SCLC) accounts for approximately15% of all lung cancers.1 Patients with SCLC usually
experience a multitude of symptoms. Cough is the most
common presenting and persistent symptom in about 75% of
patients; the other common symptoms are dyspnea in about
60% of patients, chest pain in about 49% of patients, and
hemoptysis in about 35% of patients. These symptoms often
indicate the progression of the disease and are likely to affect
patients’ physical functioning and perception of the severity
of their condition.2,3
SCLC is more aggressive than non-small cell lung
cancer, metastasizes earlier and more quickly to regional and
distant organ systems but is much more responsive to initial
chemotherapy and radiation treatment.1 Nevertheless, the
majority of SCLC patients treated with standard first-line
chemotherapy relapse after 1 year of treatment, and the
prognosis for patients receiving second-line therapy is poor.
Thereby, patients with SCLC may need to live with the
reality of a shortened life span. The 2-year survival rate for
patients with metastatic SCLC is approximately 15%.4 For
patients whose disease recurs after standard first-line plati-
num-based therapy, expected survival is measured in months,
even with the most aggressive therapies.5,6
When the benefit of chemotherapy in extending life
expectancy is limited, improving patients’ health-related
quality of life becomes an important goal of therapy. It has
been shown that symptom burden and quality of life are well
correlated; even in the absence of survival benefit, chemo-
therapy can provide palliative benefits to patients with lung
cancer.7 The association of lung cancer symptom burden and
health-related quality of life warrants the assessment of lung-
cancer-specific symptoms when evaluating the efficacy of a
new treatment in clinical trials.
A number of instruments exist to measure lung-cancer-
specific symptoms, including Lung Cancer Symptom Scale
(LCSS),8,9 Functional Assessment of Cancer Therapy—Lung
(FACT-L),10 and the European Organization for Research
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and Treatment of Cancer Quality of Life Questionnaire
Core-30 (EORTC QLQ-C30) with Quality of Life Question-
naire Lung Cancer-13 (QLQ-LC13).11,12 They differ in vari-
ous aspects, such as symptom selection, the inclusion of
global quality of life questions, type of assessment scales
(i.e., visual analogue versus numerical rating scale). Although
these instruments have been widely used since their introduc-
tion, they were originally validated in lung cancer popula-
tions that contain both patients with non-small cell lung
cancer and also with SCLC, rather than exclusively in the
population of SCLC patients. Because SCLC constitutes a
minority of lung cancer cases, SCLC patients were likely
underrepresented in the prior validation studies.
The Patient Symptom Assessment in Lung Cancer
(PSALC) was initially developed for use in the registration
trial of intravenous (IV) topotecan in treating patients with
relapsed SCLC to specifically capture the symptom burden
imposed on patients with SCLC, in particular among patients
who failed first-line chemotherapy.6 Using data from this
prior trial, a recent publication demonstrated that the PSALC
is a valid, reliable, and responsive symptom assessment
questionnaire.13
Since its original development, the PSALC instrument
has been used in over 900 patients in four multicenter clinical
trials conducted in relapsed SCLC populations receiving not
only the IV but also the oral formulation of topotecan. The
objective of the current study is to cross-validate the PSALC
instrument using the pivotal clinical trial data for oral topo-
tecan (OT) to determine if the validity findings from the
previous IV topotecan trial may also be replicated in this trial.
Instrument validation is an ongoing process, such that estab-
lishing validity in additional population settings (e.g., in this
study, in a subsequent clinical trial setting in relapsed SCLC)
should further support the evidence base for the validity of
the instrument.
MATERIALS AND METHODS
The Patient Symptom Assessment in Lung
Cancer Instrument
The PSALC instrument contains nine items measuring
the symptom burden experienced by patients with SCLC. It
contains items related to lung-cancer-specific physical symp-
toms (i.e., “shortness of breath,” “cough,” “chest pain,”
“coughing up blood,” “loss of appetite,” “interference with
sleep,” “hoarseness,” “fatigue”) and an item related to the
overall symptom burden of the disease with respect to func-
tional status (i.e., “interference with daily activities”). Ac-
cording to the protocol of the clinical trial,14 the PSALC was
administered to the patients at baseline and before each
subsequent clinical visit at 3-week intervals. Patients were
asked to evaluate how much they had experienced each
symptom (i.e., the extent to which they experienced it or were
bothered by it) during the past 3 weeks on a four-point ordinal
scale: 1 (not at all), 2 (a little), 3 (quite a bit), or 4 (very
much). Thus, a higher score indicates greater symptom bur-
den. Appendix shows the PSALC questionnaire.
Data Source
Data were used from an open-label, randomized, mul-
ticenter, phase III clinical trial in which OT in combination
with best supportive care (BSC) (N 71) was compared with
BSC alone (N  70) as second-line therapy for patients with
relapsed SCLC. Details of the clinical trial results were
published elsewhere.14 At baseline, patients with an Eastern
Cooperative Oncology Group (ECOG) score of 2 or lower,
and adequate bone marrow, liver, and renal functions were
recruited. It was recommended that patients receive at least
four courses of OT, and the duration of the treatment de-
pended on the tolerability and response. The primary end
point of the study was overall survival (all-cause mortality).
Secondary endpoints were tumor response rate, time to dis-
ease progression, symptom assessment (measured by the
PSALC), quality of life evaluation (measured by the EQ-5D),
and safety. Each patient’s tumor response was evaluated by
investigators independently as complete or partial response
(CR/PR), stable disease (SD), or progressive disease (PD),
according to the World Health Organization criteria. Never-
theless, because patients in the BSC alone arm were not
receiving chemotherapy, it was not expected that these pa-
tients would show any response. Therefore, radiologic assess-
ment of tumor response was only applied to patients random-
ized to receive OT plus BSC. The PSALC and EQ-5D were
administered to patients in both treatment arms at the baseline
and before each course of treatment, or approximately every
21 days.
Factor Analysis
To confirm that the PSALC contains only one factor as
demonstrated in a prior validation study,13 common factor
analysis was first conducted. Using the Kaiser-Guttman rule,
the number of factors was determined by the number of
eigenvalues (a measure of how much of the variation in the
data is accounted for by each factor) greater than one.15–17 In
addition, to estimate the contribution of each of the nine items
to the factor or factors present in the instrument, final com-
munality statistics were calculated. This step is needed to
determine whether one aggregate score can be used in the
validation analysis.
Internal Consistency
Three measures of internal consistency were calculated
to assess the homogeneity of the scale. Pearson correlation
coefficients were calculated for item-to-item correlation (be-
tween any two individual items) and item-to-total correlation
(between a single item and the scale total excluding that
item). In general, the threshold for a good item-to-total
correlation is no lower than 0.20 to 0.40.18,19 Cronbach’s
alpha coefficient reflects the average correlation among all
the items in the scale. It was calculated for PSALC scores
evaluated at the baseline and at four subsequent follow-up
visits, separately. A “good” alpha is typically established by
a value between 0.7 and 0.9.20
Test-Retest Reliability
The stability of a measure on the same patient from one
time to another is a desirable feature of an instrument when
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the underlying construct remains constant. The time period
between two consecutive tests should be sufficiently short to
minimize the possibility of change in the underlying construct
between two assessments. This property was evaluated by
test-retest reliability. Specifically, the correlation between the
baseline and first-visit PSALC scores was quantified by the
concordance correlation coefficient (CCC) and the intraclass
correlation coefficient (ICC) were obtained for patients be-
fore any documented clinical changes in tumor response (e.g.,
before the first documented response for patients with an
overall evaluation of CR/PR, and before the first documented
progression for patients with an overall evaluation of SD, PD,
or not determined [ND]), including the baseline PSALC
evaluations.
Using each patient’s PSALC scores at baseline and at
the first clinical visit, CCC was calculated as
CCC 
2*12
1
2  2
2  1  2
2
,
where t
1 is the variance of PSALC scores at the baseline (t
1) and the first visit (t  2), 12 is the covariance of PSALC
scores at two time points, and t is the mean PSALC score at
time t. The CCC estimates the concordance of the two
assessments by measuring the deviation from a 45-degree line
through the origin.21
ICC was calculated as
ICC 
MSB  MSW
MSB  k  1MSW
,
where MSB is the mean square error between patients, MSW is
the mean square error within patients, and k is the mean
number of PSALC evaluations per patient.22 All PSALC
scores of a patient from the period before any documented
change in tumor response were used and pooled into one
sample. That is, one patient could contribute multiple PSALC
total scores (PSALC-TSs) to the pooled sample for the
analysis. ICC estimates the proportion of the total variance in
PSALC-TSs that can be explained by variation between
patients as opposed to the variation within patients. The
larger the ICC, the less the variation in PSALC-TSs from
within patients contributes to the total variance, indicating
higher stability of the PSALC over time.
Construct Validity
Multiple hypotheses were tested to evaluate the con-
struct validity of the PSALC. The associations between
PSALC scores and established measures, e.g., clinical mark-
ers or health-related quality of life, were estimated.
Using a contrasted group approach, the associations
between symptom burden and clinical status were tested.
Clinical status was measured by two clinical markers: the
baseline ECOG performance status and the overall tumor
response during the study period. It was hypothesized that
better the clinical status, lower the lung cancer symptom
burden. ECOG performance status was categorized as 0
(normal activity, asymptomatic), 1 (symptomatic, but fully
ambulatory), and 2 (symptomatic, in bed less than 50% of
normal daytime). Therefore, higher the ECOG score was,
higher the PSALC score was expected to be.
Similarly, patients’ overall tumor response was classi-
fied as CR/PR, SD, and PD. It was hypothesized that patients
with CR/PR had the lowest PSALC scores, patients with PD
had the highest PSALC score, and patients with SD had
PSALC scores falling in between. Tumor response evaluation
reflected the best overall response during the course of the
treatment. If a patient had more than one PSALC evaluation
during the specified follow-up period, the average of the
multiple PSALC scores for each individual patient was used
in the analysis. Because patients treated with BSC alone were
not evaluated for their tumor response per protocol, this
hypothesis test was conducted only among patients treated
with OT plus BSC.
The global difference in mean PSALC scores between
the three ECOG performance status groups were first tested
using F test. If a significant global difference was detected, a
post hoc Tukey’s test was conducted to test the differences
between pairwise comparison groups (e.g., between ECOG 
0 and ECOG  1 groups). A linear regression of baseline
PSALC score as explained by ECOG performance status was
performed to test the direction and the degree of association
between lung cancer symptom burden and performance sta-
tus. A significant and high degree of association, as reflected
by the degree of the linear slope, would support the construct
validity. Likewise, the above-described tests and regression
were conducted to test the association between PSALC scores
and tumor response.
In addition, the associations between changes in clini-
cal status and changes in symptom burden were also tested. It
was hypothesized that patients with improved clinical status
would experience reduced symptom burden. Two specific
relations were tested among the OT plus BSC group for their
availability of clinical tumor response data. First, patients’
PSALC scores during the specified study period were com-
pared with the baseline to investigate whether patients with
CR/PR would experience reduced symptom burden during
the response period, patients with PD experience increased
symptom burden during the progression period, and patients
with SD have similar symptom burden during the stable
period as at the baseline. Only patients with PSALC evalua-
tions collected at the baseline and during the specified fol-
low-up periods were included. The difference in PSALC
score changes from baseline to the follow-up period was also
tested between tumor response groups (i.e., CR/PR versus SD
and CR/PR versus PD) using Student’s t test. Second, PSALC
scores evaluated at different follow-up periods (i.e., response,
stable, and progression periods) within the same individual
were compared to examine whether patients’ symptom bur-
den varied according to different tumor response periods.
Specifically, PSALC scores evaluated during the response
period were compared with the scores evaluated during
the progression and stable period for patients with CR/PR.
PSALC scores evaluated during the stable period were com-
pared with scores evaluated during the progression period for
patients with no documented response (i.e., SD, PD, or ND).
If a patient underwent the PSALC evaluation more than once
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during the specified period, the mean of the patient’s PSALC
scores was used in the analysis. The differences in the
PSALC scores in the two relevant comparison periods were
tested using paired t test.
The construct validity of the PSALC was further inves-
tigated by benchmarking with EQ-5D—an established and
standardized preference-based instrument for use as a mea-
sure of health outcomes—to support the correlation between
lung cancer symptoms and health-related quality of life.7 The
EQ-5D instrument has two parts: a three-level, five-dimen-
sion health status profile that can be converted into a single
utility index and a visual analog scale (VAS), where the best
health status is indicated by a score of 100 and the worst
health status by 0. Pearson product-moment correlation co-
efficients were calculated to test whether PSALC scores were
negatively correlated with EQ-5D utility index and EQ-5D
VAS score.
Responsiveness
Three responsiveness indexes were calculated in this
study to measure the ability of the PSALC instrument to
detect clinically meaningful changes, including the effect
size, standardized response mean, and responsiveness statistic
(RS), defined as follows:
Effect size  D/SD0
Standardized response mean  D/SD*
RS  D/SD#
where D is raw score change, SD0 is standard deviation of
raw scores at the baseline, SD* is standard deviation of raw
score change (D), and SD# is standard deviation of raw score
change among patients with SD.
A higher RS would indicate greater sensitivity of the
PSALC instrument to changes in clinical status. The sensi-
tivity is generally considered small for a RS in the range 0.20
to 0.49, moderate for 0.50 to 0.79, and large for 0.80.23
The RSs were estimated for two different clinical situ-
ations among the OT plus BSC group for the availability of
the tumor response measurements. First, PSALC scores eval-
uated during the response period were compared with those at
the baseline among patients with CR/PR to estimate the
responsiveness of the PSALC instrument to the improvement
in the clinical status. Second, PSALC scores evaluated during
the progression period were compared with those at the
baseline and during stable period, respectively, among pa-
tients with no documented response (SD/PD/ND) to estimate
the responsiveness of the PSALC instrument to deterioration
in the clinical status.
RESULTS
Study Populations
The trial recruited 71 patients in the OT plus BSC arm
and 71 patients in the BSC alone arm. Table 1 shows the
demographic and baseline clinical characteristics by treat-
ment group, along with the distribution of patients’ overall
evaluation of tumor response to the treatment. The two groups
were similar in age, gender, and race distributions and baseline
ECOG scores and cancer stages. In patients treated with OT plus
BSC who were evaluated for tumor response, no patient expe-
rienced CR whereas about 50% of the patients had a PR or were
on stable status (5 achieved PR and 31 had SD, respectively),
and about one third of the patients had disease progression (i.e.,
24 patients), and the remaining 11 patients were not evaluable
because of premature withdrawal from the study or because their
lesion assessments were insufficient to confirm a response. In
addition, no patients with CR/PR had PSALC evaluations dur-
ing both the response and progression periods. Table 2 displays
the distribution of responses to each PSALC item at baseline.
These results show that most patients experienced no or a little
bit of most of the symptom items, particularly “coughing up
blood” and “hoarseness.” As demonstrated in Table 3, the
number of completed questionnaires (including PSALC, EQ-5D
utility index and EQ-5D VAS) decreases over time in both
treatment groups.
Factor Analysis
Factor analysis using baseline and on-treatment
PSALC scores, respectively indicated that the instrument was
TABLE 1. Demographic and Baseline Clinical Characteristics
and Overall Tumor Response, by Treatment Group
Treatment Group
Oral
Topotecan 
BSC (N  71)
BSC Alone
(N  70)
N % N %
Demographic characteristics
Age, yrs
Mean 59.8 58.6
SD 9 8.2
Range 37–76 43–79
Gender
Female 19 27 19 27
Male 52 73 51 73
Race
White 70 98.6 70 100.0
Black 1 1.4 0 0.0
Baseline disease characteristics
ECOG performance status
0 8 11.3 6 8.6
1 44 62.0 41 58.6
2 19 26.8 23 32.9
Disease stage
Limited 23 32.4 27 38.6
Extensive 48 67.6 43 61.4
Best response to treatmenta
Complete response 0 0.0 n/a
Partial response 5 7.0 n/a
Stable disease 31 43.7 n/a
Progressive disease 24 33.8 n/a
Not assessable 11 15.5 n/a
a Response to treatment was not assessed in the BSC alone group.
BSC, best supportive care; ECOG, Eastern Oncology Cooperative Group.
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measuring a single construct, as only one eigenvalue was
greater than 1. Therefore, the sum of the nine item scores (the
PSALC-TS) was used for the validation analysis. The item
that contributed the least to the single factor was “coughing
up blood,” with a final communality estimate of 0.0717.
Internal Consistency
Using baseline PSALC evaluations, Pearson item-to-
item correlation coefficients were statistically significant (p
0.05) in most items, except for correlations between “cough-
ing up blood” and several other items (“chest pain,” “loss of
appetite,” “interference with sleep,” “hoarseness,” and “fa-
tigue”), correlations between “chest pain” and several other
items (“shortness of breath,” “cough,” and “hoarseness”), and
the correlations between “hoarseness” and two items (“loss of
appetite” and “fatigue”). Item-to-total correlations were high
and significant (range, 0.42–0.69, p  0.01) for all items
except for “chest pain” (0.271), “coughing up blood” (0.224),
and “hoarseness” (0.273). Analyses using on-treatment
PSALC evaluations found similar results for item-to-item and
item-to-total correlations. Table 4 shows that the Cronbach’s
alpha coefficient was 0.77 using baseline PSALC scores and
was greater than 0.7 (range, 0.76–0.83) using PSALC eval-
uations at each follow-up visit.
Test-Retest Reliability
The CCC was 0.69, indicating that PSALC-TSs at the
baseline were reproducible at the first visit. The ICC was
0.68, suggesting that 68% of the total variance among
PSALC-TSs is because of the variance between patients
rather than variance within patients.
Construct Validity
Patients with worse performance status (i.e., higher
ECOG scores) on average had greater symptom burden (i.e.,
higher PSALC-TSs) compared with patients with better per-
formance status (i.e., lower ECOG scores). Specifically, the
mean PSALC-TSs were 17.58, 16.37, and 12.31 for patients
with ECOG scores of 2, 1, and 0, respectively (p  0.0002)
(Table 5). Furthermore, the post hoc Tukey test showed that
the PSALC-TSs were different between score levels 0 versus
1 and 0 versus 2 (p  0.05). A linear regression of the
PSALC-TS on ECOG performance status at baseline gener-
ated a coefficient of 2.15 (p  0.0002), indicating a high
degree of positive association between ECOG performance
status and lung cancer symptom burden (Figure 1).
Patients with an overall evaluation of CR/PR were
found to have the lowest symptom burden on average (i.e.,
mean PSALC-TS  12.68), and patients with overall evalu-
ation of PD were found to have the highest symptom burden
on average (i.e., mean PSALC-TS  18.45), and patients
with overall evaluation of SD had a mean PSALC-TS (15.26)
between those of patients with CR/PR and PD (p  0.0077)
(see Table 6). A linear regression of the PSALC-TS on
overall tumor response generated a slope of 2.96 (p 
TABLE 4. Cronbach’s Alpha Coefficients, Using PSALC Total
Scores Evaluated at the Baseline and the Subsequent Clinical
Visits (up to the Last Recommended Treatment Cycle)
Baseline Cycle 1 Cycle 2 Cycle 3 Cycle 4
Sample size in
cycle
132 102 84 72 51
Cronbach’s alpha
in sample
0.7737 0.8261 0.7607 0.7739 0.7781
In general, Cronbach’s alpha between 0.7 and 0.9 is considered good.
TABLE 5. Mean PSALC Total Scores by Baseline ECOG
Performance Status
ECOG Performance
Statusa
Mean PSALC
Total Score
Standard
Deviation F-Test p
0 (N  13) 12.31 2.29
0.00021 (N  79) 16.37 3.72
2 (N  40) 17.58 4.35
a ECOG performance status: 0  Normal activity, asymptomatic; 1  Symptom-
atic, but fully ambulatory; 2  Symptomatic, in bed in less than 50% of normal daytime.
Only patients with both ECOG and PSALC scores at baseline were included in this
analysis.
PSALC, Patient Symptom Assessment in Lung Cancer; ECOG, Eastern Oncology
Cooperative Group.
TABLE 2. Distribution of Patients’ Responses to Each PSALC
Item at Baseline
Symptom N
1 Not
at All
2 A
Little
3 Quite
a Bit
4 Very
Much
Shortness of breath 136 21.3% 57.4% 17.7% 3.7%
Cough 135 17.8% 60.7% 17.8% 3.7%
Chest pain 135 50.4% 37.0% 8.9% 3.7%
Coughing up blood 136 89.0% 10.3% 0.0% 0.7%
Loss of appetite 136 47.1% 38.2% 11.8% 2.9%
Interference with sleep 135 40.7% 42.2% 13.3% 3.7%
Hoarseness 135 63.0% 25.9% 11.1% 0.0%
Fatigue 136 14.0% 47.1% 34.6% 4.4%
Interference with daily
activities
136 25.7% 36.0% 29.4% 8.8%
PSALC, Patient Symptom Assessment in Lung Cancer; N, number of patients.
TABLE 3. Number of Completed Questionnaires at Baseline
and at Subsequent Clinical Visits (up to the Last Recommended
Treatment Cycle)
Baseline
Cycle
1
Cycle
2
Cycle
3
Cycle
4
PSALC
Oral topotecan 	 BSC 69 60 48 43 32
BSC alone 63 42 36 29 19
EQ-5D utility index
Oral topotecan 	 BSC 69 63 53 45 33
BSC alone 68 49 39 30 22
EQ-5D VAS
Oral topotecan 	 BSC 67 63 53 45 33
BSC alone 66 47 39 30 22
PSALC, Patient Symptom Assessment in Lung Cancer; BSC, best supportive care;
VAS, visual analog scale.
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0.0018), indicating a high degree of a positive association
between tumor response and lung cancer symptom burden
(Figure 2).
Changes in clinical status and changes in symptom
burden were also found to be strongly correlated. Specifi-
cally, patients with CR/PR on average experienced a signif-
icant reduction in PSALC-TSs during response period com-
pared with the baseline (score change 2.43, p 0.0093),
patients with SD on average had similar PSALC-TSs during
the stable period compared with the baseline (score change 
0.01, p  0.9502), and patients with PD on average tended to
experience an increase in PSALC-TSs during the progression
period compared with the baseline, though the change did not
reach statistical significance (score change  2.50, p 
0.1266). Further, patients with CR/PR experienced a signif-
icant reduction in symptom burden from baseline to the
response period compared with patients with SD (p 
0.0016) or PD (p  0.0046) (Table 7).
Within the same individual, paired changes in PSALC-
TSs and clinical status were also found. Specifically, among
patients with overall evaluation of CR/PR, PSALC-TSs eval-
uated before tumor response were higher than their scores
during the response period (13.83 versus 13.44, p  0.6449),
albeit not reaching statistical significance. Among patients
with no documented response (SD/PD/ND), PSALC-TSs
were significantly lower during the stable period compared
with their scores during the progression period (15.39 versus
17.76, p  0.0007).
Patients with greater symptom burden were found to
have a lower quality of life. PSALC-TSs were significantly
negatively correlated with EQ-5D utility index (Pearson cor-
relation coefficient  0.598, p  0.001, n  490) and
EQ-5D VAS score (Pearson correlation coefficient 
0.594, p  0.001, n  485), using evaluations pooled from
all trial visits, and at each trial visit (Table 8). Similar results
were found for correlations between EQ-5D quality of life
measures and each individual PSALC item.
Responsiveness
Among patients with CR/PR, the RSs estimated by
comparing PSALC-TSs evaluated during the response period
with the baseline were 0.98 for effect size, 0.78 for
standardized response, and 0.99 for RS. Among patients
with no documented tumor response, the RSs estimated by
comparing PSALC-TSs evaluated during the progression
period with that at baseline were 0.58 for effect size, 0.54 for
standardized response, and 1.12 for RS; the RSs estimated by
comparing PSALC-TSs evaluated during progression period
with those during the stable period were 0.87 for effect size,
0.94 for standardized response, and 1.11 for RS. These results
suggested that the PSALC instrument is sensitive in detecting
underlying changes in clinical status.
DISCUSSION
SCLC accounts for a small proportion of lung cancers
and has distinctive disease characteristics compared with
other types of lung cancer. Patients with SCLC usually
experience detrimental lung cancer symptoms and impaired
quality of life. Given that chemotherapies provide limited
survival benefit, symptom relief becomes a crucial criterion
in the choice of chemotherapies. Through a prior retrospec-
tive validation study using the data from the registration
clinical trial of IV topotecan, the PSALC was demonstrated
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FIGURE 1. Linear association between
PSALC-TS and ECOG performance status (0, 1,
2) at baseline.
TABLE 6. Mean PSALC Total Scores by Overall Tumor
Response Evaluation, for Patients Receiving Oral Topotecan
Plus BSC
Tumor Response
Evaluation
Mean PSALC
Total Score
Standard
Deviation
F Test
p
CR/PR (n  5) 12.68 2.46
0.0077SD (n  31) 15.26 3.07
PD (n  11) 18.45 4.89
PSALC, Patient Symptom Assessment in Lung Cancer; BSC, best supportive care;
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease.
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to be a reliable, valid, and sensitive instrument.13 The purpose
of this study is to confirm the psychometric properties of the
PSALC using data from the pivotal registration clinical trial
for the oral formulation of topotecan.
This study replicated the previously established psy-
chometric properties of the PSALC instrument.13 Factor anal-
ysis showed that the PSALC instrument contains one single
dimension. The item “coughing up blood” contributed the
least to the single composite construct and may be measuring
a somewhat different concept than the other items. Neverthe-
less, as in the previous study, the final communality estimate
was not low enough to suggest that this item should be
grouped separately from the others. The homogeneity of the
PSALC was demonstrated by Cronbach’s alpha coefficients
greater than the 0.7 threshold for the baseline PSALC eval-
uation (0.77) and for PSALC evaluations from follow-up
visits during the course of the clinical trial (range, 0.76–
0.83), similar to the 0.78 at baseline and 0.67 to 0.79 at
0
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FIGURE 2. Linear association between
PSALC-TS and overall tumor response evalua-
tion (0  CR/PR, 1  SD, 2  PD).
TABLE 7. Change in Mean PSALC Total Scores from Baseline to Follow-up Period, by Overall Tumor Response Evaluation, for
Patients Receiving Oral Topotecan Plus BSC
No. Baseline Follow-up Pa Pb
PSALC Evaluations Patients Mean Std Mean Std (follow-up vs. baseline) (CR/PR vs. SD) (CR/PR vs. PD)
Patients receiving
OT 	 BSC
CR/PR 14 5 15.07 1.98 12.64 2.68 0.0093
0.0016 0.0046SD 141 31 15.33 3.54 15.35 3.34 0.9502
PD 10 10 15.80 3.43 18.30 5.12 0.1266
a Paired t test.
b Pairwise t test on difference in PSALC total score change between response groups.
PSALC, Patient Symptom Assessment in Lung Cancer; OT, oral topotecan; BSC, best supportive care; CR, complete response; PR, partial response; SD, stable disease; PD,
progressive disease; Std, standard deviation.
TABLE 8. Correlation of PSALC and EQ-5D Scores
EQ-5D Measure
PSALC Total Score
All Scores Baseline Visit 1 Visit 2 Visit 3 Visit 4
EQ-5D utility index 0.598a 0.489a 0.644a 0.694a 0.501a 0.662a
N 490 126 101 83 69 51
EQ-5D VAS score 0.594a 0.503a 0.645a 0.648a 0.553a 0.577a
N 485 123 99 83 69 51
a p  0.001.
PSALC, Patient Symptom Assessment in Lung Cancer.
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follow-up visits found previously. The stability (reproducibil-
ity) of the PSALC on the same patients over time when the
underlying construct remained stable was supported by test-
retest reliability—CCC of 0.69 and ICC of 0.68, consistent
with 0.71 and 0.61 revealed previously. The construct valid-
ity of the PSALC was supported by evaluating the association
with established clinical benchmarks, ECOG performance
status, and tumor response, as in the previous study, and was
further enhanced by the significant correlation with EQ-5D
quality of life scores which were not collected in the previous
study. The responsiveness of the PSALC instrument to un-
derlying changes in patients’ tumor response status was
demonstrated by the three responsiveness indexes (i.e., effect
size, standardized response, and RSs) greater than 0.80. In
comparison, the prior study found that the estimated RSs all
fell in the small to moderate range.
This cross-validation study shares several limitations
with the original validation study.13 First, the study is limited
by its retrospective study design. If feasible, a validation
study on prospectively collected data could be conducted to
further confirm the findings reported here. Second, the sta-
bility of the PSALC as measured by CCC (0.69) and ICC
(0.68) in this study was somewhat lower than that of another
well-developed lung cancer instrument LCSS validated in all
lung cancer populations (Pearson correlation coefficient of
0.75).8 Two factors might contribute to the discrepancy (1).
The instruments were administered at different frequencies.
In the LCSS validation study, LCSS was reevaluated 1 hour
after the initial evaluation, whereas in the present clinical trial
the PSALC was administered every 3 weeks between subse-
quent clinical visits (2). Patients’ underlying condition may
have changed even though it was not readily detected by
tumor response evaluation, as SCLC is a progressive and
deteriorative disease.
Third, the generalizability of the findings for construct
validity and responsiveness is limited by the relatively small
sample size that can be used for the analysis. Given that
SCLC is a minority of lung cancer cases, the trial was able to
enroll only 141 patients. Further, patients treated with BSC
alone were not evaluated for tumor response, hence were not
included for any analysis that relied on tumor response
evaluation. In addition, only 5 of 71 patients on OT plus BSC
achieved partial tumor response (with 31 achieving SD);
however, tumor response may have been underreported as the
response rate was a secondary end point of the trial. Also, for
comparisons between different periods, only patients with at
least one PSALC evaluation at each of the comparison
periods were included. In particular, among the 24 patients
with an overall tumor response evaluation of PD, only 10
patients had both a baseline PSALC evaluation and at least
one PSALC evaluation available during the period of disease
progression. Therefore, even though patients with PD on
average tended to experience an increase in PSALC-TSs
during the progression period compared with the baseline, the
change did not reach statistical significance. For the same
reason, even though patients with CR/PR on average tended
to experience a decrease in PSALC-TSs during the response
period compared with that before response, the difference did
not reach statistical significance (n  4). The available data
for analysis were further diminished by patient withdrawals
because of adverse events, protocol violations, loss to follow-
up, or various other reasons (i.e., withdrawals were 21 of 71
[30%] in OT plus BSC and 33 of 70 [37%] in BSC alone).
The findings from this cross-validation study confirm
the validity of the PSALC instrument as a measure of SCLC
symptoms in previously treated patients. As an instrument
with only nine symptom items on an ordinal rating scale, the
PSALC is feasible and easily applicable not only in formal
clinical trial settings, but also in routine clinical practice. The
PSALC instrument quantifies the lung cancer symptoms re-
ported by the patients during the course of chemotherapy, and
thus provides a potential tool to monitor patients’ condition,
in addition to clinical examination and traditional imaging.
This retrospective psychometric cross-validation analysis
using clinical trial data confirms the psychometric properties of
the PSALC found in a prior study and further supports the use of
the PSALC instrument for measuring lung-cancer-specific
symptoms in a previously treated SCLC population.
ACKNOWLEDGMENTS
This research was sponsored by GlaxoSmithKline, Col-
legeville, PA.
REFERENCES
1. Ihde DC, Pass HI, Glatstein E. Small cell lung cancer. In VT Devita, S
Hellman, SA Rosenberg, (Eds.), Cancer: Principles & Practice of On-
cology, 5th ed. Philadelphia, PA: Lippincott-Raven, 1997. P. 911.
2. Bergman B. Psychosocial issues in the treatment of patients with lung
cancer. Lung Cancer 1992;8:1–20.
3. Beckles MA, Spiro SG, Colice GL, et al. Initial evaluation of the patient
with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic
syndromes. Chest 2003;123:97S–104S.
4. Ardizzoni A, Tjan-Heijnen VC, Postmus PE, et al. Standard versus
intensified chemotherapy with granulocyte colony-stimulating factor
support in small-cell lung cancer: a prospective European Organization
for Research and Treatment of Cancer-Lung Cancer Group Phase III
Trial-08923. J Clin Oncol 2002;20:3947–3955.
5. Albain KS, Crowley JJ, Hutchins L, et al. Predictors of survival follow-
ing relapse or progression of small cell lung cancer. Southwest Oncology
Group Study 8605 report and analysis of recurrent disease data base.
Cancer 1993;72:1184–1191.
6. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclo-
phosphamide, doxorubicin, and vincristine for the treatment of recurrent
small-cell lung cancer. J Clin Oncol 1999;17:658–667.
7. Gralla RJ. Quality-of-life considerations in patients with advanced lung
cancer: effect of topotecan on symptom palliation and quality of life.
Oncologist 2004;9(suppl 6):14–24.
8. Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life assessment in
individuals with lung cancer: testing the Lung Cancer Symptom Scale
(LCSS). Eur J Cancer 1993;29A(suppl 1):S51–S58.
9. Hollen PJ, Gralla RJ, Kris MG, et al. Measurement of quality of life in
patients with lung cancer in multicenter trials of new therapies: psychomet-
ric assessment of the Lung Cancer Symptom Scale. Cancer 1994;73:2087–
2098.
10. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the
Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of
life instrument. Lung Cancer 1995;12:199–220.
11. Aaronson NK, Ahmedzai A, Bergman B, et al. The European Organi-
zation for Research and Treatment of Cancer QLQ-C30: a quality-of-life
instrument for use in international clinical trials in oncology. J Natl
Cancer Inst 1993;85:365–376.
Chen et al. Journal of Thoracic Oncology • Volume 3, Number 10, October 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer1144
12. Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-
LC13: a modular supplement to the EORTC Core Quality of Life
Questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J
Cancer 1994;30A:635– 642.
13. Chen L, Antras L, Duh M, et al. Psychometric validation of the Patient
Symptom Assessment in Lung Cancer instrument for small cell lung
cancer. Curr Med Res Opin 2007;23:2741–2762.
14. O’Brien MER, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing
supportive care alone with supportive care with oral topotecan in
patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:
5441–5447.
15. Guttman L. Some necessary conditions for common factor analysis.
Psychometrika 1954;19:149–161.
16. Kaiser HE. The application of electronic computers to factor analysis.
Educ Psychol Meas 1960;20:141–151.
17. Kaiser HE. A note on Guttman’s lower bound for the number of
common factors. Br J Stat Psychol 1961;14:1.
18. Kline P. A Handbook of Psychological Testing. London: Routledge,
1993.
19. Ware JE Jr, Harris WJ, Gandek B, et al. MAP-R for Windows: Multi-
trait/Multi-Item Scale Analysis Software. Boston, MA: Health Assess-
ment Lab, 1997.
20. Nunnally JC. Psychometric Theory, 2nd Ed. New York, NY: McGraw-
Hill, 1978.
21. Lin LI-K. A concordance correlation coefficient to evaluate reproduc-
ibility. Biometrics 1989;45:255–268.
22. Shrout PE, Fleiss JL. Intraclass correlation: use in assessing rater
reliability. Psychol Bull 1979;86:420–428.
23. Cohen J. Statistical Power Analysis for the Behavioral Sciences, Revised
edition. New York, NY: Academic Press, 1977.
APPENDIX
Patient Symptom Assessment in Lung Cancer Instrument
Journal of Thoracic Oncology • Volume 3, Number 10, October 2008 Cross-Validation of the PSALC Instrument
Copyright © 2008 by the International Association for the Study of Lung Cancer 1145
